Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents. 1993

L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens 30602.

The beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanylpyrimidine and -purine nucleosides with natural nucleoside configuration were synthesized and evaluated against HIV-1 in human peripheral blood mononuclear (PBM) cells. The key intermediate 14, which was utilized for the synthesis of various nucleosides, was synthesized from D-mannose or D-galactose. Condensation of the acetate 14 with thymine, uracil, cytosine, and 5-substituted uracils and cytosines gave various pyrimidine nucleosides. The acetate 14 was also condensed with 6-chloropurine and 6-chloro-2-fluoropurine which were converted to various purine nucleosides. In the case of thymine, uracil, and 5-substituted uracil derivatives, most of the compounds did not exhibit any significant anti-HIV activity except 5-fluorouracil (alpha-isomer) derivative 55. Among 5-substituted cytosine analogues, 5-bromocytosine derivative (beta-isomer) 68 was found to be the most potent anti-HIV agent. In the case of purine derivatives, inosine analogue (beta-isomer) 78 was found to be the most potent anti-HIV agent in the 6-substituted purines and 2-amino-6-chloropurine derivative (beta-isomer) 90 showed the most potent activity in the 2,6-disubstituted purine series. The beta-isomers of 6-chloropurine (74), adenine (76), and N6-methyladenine (77) derivatives showed similar potencies against HIV-1, and the corresponding alpha-isomers also exhibited significant anti-HIV activity, although they were generally less potent than the beta-isomers.

UI MeSH Term Description Entries
D007042 Hypoxanthines Purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism.
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D003596 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
June 2004, Journal of medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
March 2002, Journal of medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
January 2001, Nucleosides, nucleotides & nucleic acids,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
August 2009, Bioorganic & medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
January 1991, Pharmaceutical research,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
January 1991, Nucleic acids symposium series,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
June 1999, Journal of medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
May 2018, Molecular diversity,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
July 2017, Molecules (Basel, Switzerland),
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and K Shanmuganathan, and S Nampalli, and M W Chun, and W K Chung, and B G Choi, and C K Chu
March 1996, Carbohydrate research,
Copied contents to your clipboard!